Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265511 · ClinicalTrials.gov registry record · Phase 2
Study of SCY-635, Pegasys and Copegus in Hepatitis C
A Phase 2 study, sponsored by Scynexis.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01265511 is a Phase 2 study that has completed, run by Scynexis. The registered enrollment target is 10 participants.
The verdict
NCT01265511, a Phase 2 study, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will examine the effectiveness of 28 days of triple combination therapy including SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An additional 20 weeks of treatment with the currently approved standard of care will be offered to all participants. The Week 24 visit will be the last on-study visit. After the Week 24 visit, all subjects with undetectable HCV RNA will be given the option to continue treatment with standard of care for an additional 24 weeks (out to Week 48) under the care of their Principal Investigator.
Interventions
- DRUG Placebo
- DRUG Copegus
- DRUG Pegasys
- DRUG SCY-635
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01265511
The ClinicalTrials.gov registry entry for NCT01265511 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scynexis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01265511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01265511 about?
NCT01265511 is a clinical study titled "Study of SCY-635, Pegasys and Copegus in Hepatitis C". This study will examine the effectiveness of 28 days of triple combination therapy including SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An additional 20 weeks of treatment with the currently approved standard of care will be offered to all participants. The We...
What is the current status of trial NCT01265511?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01265511?
The interventions under investigation include: Placebo (DRUG), Copegus (DRUG), Pegasys (DRUG), SCY-635 (DRUG).
Who is sponsoring clinical trial NCT01265511?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.